SEATTLE, Jan. 7, 2008 (PRIME NEWSWIRE) -- Keller Rohrback L.L.P. announces that it is investigating claims by heart surgery patients that have suffered kidney failure, a heart attack, or a stroke as a result of being given Trasylol (aprotinin injection), a heart surgery drug. Pressured by regulators around the world, including the U.S. Food and Drug Administration, on November 5, 2007, Bayer A.G. agreed to a phased withdrawal of Trasylol from the United States market. If you or someone you know may have been injured following heart surgery as a result of being given Trasylol, please contact attorney Michael Woerner for a free consultation toll free at 800/776-6044.
Keller Rohrback L.L.P. has successfully represented hundreds of clients injured by prescription drugs such as Fen-Phen, Baycol, and Vioxx. Our Complex Litigation Group is proud to offer its expertise in personal injury cases to clients nationwide.